-
The survival data of the IMpower010 study was published for the first time, consolidating atezolizumab as the standard adjuvant therapy!
Time of Update: 2022-08-19
Previous data from IMpower010 (NCT02486718) demonstrated a statistically significant benefit in disease-free survival (DFS) with atezolizumab compared with best supportive care (BSC) in patients with NSCLC resected after platinum-based chemotherapy: PD-L1 tumor cells (TC) ≥ 1% II-IIIA patients (DFS HR=0.
-
European Radiology: Measurement of this imaging marker predicts chemotherapy-associated steatohepatitis in breast cancer patients receiving NAC!
Time of Update: 2022-08-19
A study published in European Radiology recently quantified liver fat content by MRI mDIXON-Quant examination to determine the prevalence of CASH, and semi-automated volume analysis software to measure EAT volume on chest CT to explore BC patients after NAC.
-
J Ethnopharmacol: Combining network pharmacology and transcriptomic validation to study the efficacy and mechanism of Mufangji decoction in the prevention of lung cancer
Time of Update: 2022-08-19
The targets and pathways of MFJD in the treatment of lung cancer were obtained through protein-protein interactions, molecular docking, and the David database, and the predicted results were validated in vitro and in vivo .
-
J Clin Oncol: Long-term outcomes of rituximab combined with lenalidomide or chemotherapy in follicular lymphoma
Time of Update: 2022-08-19
The RELEVANCE trial is a Phase 3 clinical trial to compare lenalidomide + rituximab (R2) vs rituximab + chemotherapy (R-chemo) in patients with previously untreated advanced FL efficacy and safety .
-
British Journal of Cancer: Eat while it's hot, it will cause cancer
Time of Update: 2022-08-19
Recently, the team of Li Zhiyuan from Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences published a research paper entitled: Thermal stress involved in TRPV2 promotes tumorigenesis through the pathways of HSP70/27 and PI3K/Akt/mTOR in esophageal squamous cell carcinoma in the British Journal of Cancer.
-
Professor Wang Shusen: HER2 redefines a new chapter in breast cancer targeted therapy
Time of Update: 2022-08-19
The APHINITY study found that the overall ITT population continued to achieve significant benefit, and adjuvant trastuzumab + pertuzumab treatment in patients with HER2-positive eBC further reduced the risk of recurrence by 24% .
-
NEJM: Teclistamab in relapsed/refractory multiple myeloma
Time of Update: 2022-08-19
This is a Phase 1-2 study enrolling patients with relapsed or refractory multiple myeloma after at least three lines of therapy, including three classes of exposure to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies .
-
Chinese and Western medicine work together to promote the comprehensive management of tumors
Time of Update: 2022-08-19
In order to improve the diagnosis and treatment of breast cancer and prolong the survival period of patients, the medical community has continuously explored the treatment rules of traditional Chinese medicine combined with surgery, radiotherapy and chemotherapy, and targeted therapy, and has carried out many high-level evidence-based clinical studies .
-
Science sub-journal: Disturbance of the biological clock can directly accelerate the progression of colorectal cancer!
Time of Update: 2022-08-19
html Introduction: An alarming increase in the incidence of colorectal cancer (CRC) in young adults has been reported; however, the underlying molecular mechanisms remain undefined .
html Introduction: An alarming increase in the incidence of colorectal cancer (CRC) in young adults has been reported; however, the underlying molecular mechanisms remain undefined .
-
Cohort study of 1.5 million young women: Contraceptive pill increases cancer risk 10 years after discontinuation!
Time of Update: 2022-08-19
Numerous studies have shown that current and recent combined oral contraceptive users have a slightly increased relative risk of breast cancer that fades within five to ten years after HC discontinuation .
-
J Clin Oncol: Maintenance therapy with rucaparib after chemotherapy in DNA repair-deficient metastatic urothelial carcinoma
Time of Update: 2022-08-19
DRD biomarker-positive mUC patients without cancer progression within 10 weeks of chemotherapy were randomized (1:1) to rucaparib (600 mg twice daily) or placebo and maintained until disease progress .
-
Chinese Academy of Sciences: Repeated heating can promote the formation and spread of esophageal squamous cell carcinoma!
Time of Update: 2022-08-19
Recently, the British Journal of Cancer (British Journal of Cancer) and Cancer Research UK (Cancer Research UK) jointly published a report titled "Heat stress is involved in TRPV2 through HSP70/HSP70/ 27 and PI3K/Akt/mTOR pathway promotes tumorigenesis in esophageal squamous cell carcinoma” (Thermal stress involved in TRPV2 promotes tumorigenesis through the pathways of HSP70/27 and PI3K/Akt/mTOR in esophageal squamous cell carcinoma) .
-
How to diet, exercise and weight management for cancer patients during treatment?
Time of Update: 2022-08-19
(Quality of evidence: low, Strength of recommendation: weak)Note: Exercise intervention during treatment can reduce fatigue, maintain cardiorespiratory fitness, physical function, and strength, and to some extent improve quality of life and reduce anxiety and depression .
-
JAMA Netw Open: Are prostate cancer drugs gonadotropin-releasing hormone agonists associated with cardiovascular disease risk and hypertension in men with diabetes?
Time of Update: 2022-08-19
Cumulative incidence of cardiovascular diseaseIn conclusion, in this population-based cohort study, men with type 2 diabetes who received GnRH agonists for PCa had an increased risk of CVD .
-
Nat Med: Clinical study confirms that ADC drug can effectively treat brain metastases from breast cancer
Time of Update: 2022-08-19
This phase 2 clinical trial confirmed that the HER2-targeting antibody-drug conjugate (ADC) drug Trastuzumab deruxtecan can effectively treat or even clear brain metastases in patients with HER2-positive breast cancer .
-
Olapali challenged SCLC single-handedly, and early trials showed initial results
Time of Update: 2022-08-19
However, a sensitivity analysis that excluded 5 patients who were randomized due to disease progression after primary therapy showed a statistically significant PFS for olaparib BD compared with placebo (HR = 0.
-
Radiology: The Powerful Combination of CT+CA19-9: Evaluation of Treatment Response in Nonmetastatic Pancreatic Cancer
Time of Update: 2022-08-19
A study published in the journal Radiology examined the effectiveness of combined assessment of CT (CT response) and CA 19-9 response in predicting overall survival (OS) in patients with non-metastatic PDAC at 8 weeks after initiation of first-line therapy.
-
Nature sub-journal: Scientists reveal the cause of colon cancer recurrence after chemotherapy!
Time of Update: 2022-08-19
Due to the effects of the drugs used in this treatment, these cells adopt an embryonic-like state, and at some point after chemotherapy, when the environment is more favorable, they are reactivated to regenerate the tumor in all its complexity .
-
Wang Jie/Tang Fuqun/Hejie found that mixed lineage cancer cells are widely present in lung cancer patients!
Time of Update: 2022-08-19
This study used high-precision single-cell transcriptome sequencing technology to systematically analyze the molecular characteristics of human primary non-small cell lung cancer, and identified a new group of mixed lineage tumor cells at the single-cell transcriptome level and their key biological characteristics.
-
Gut: Ma Yanlei's team from Fudan University reveals the characteristics of intestinal flora, metabolites and bacterial enzymes in young colorectal cancer
Time of Update: 2022-08-19
Are there pathogenic bacteria and metabolite profiles with diagnostic value in young patients with colorectal cancer?Are these microbiota and metabolites important pathogenic factors in the development of intestinal cancer in young adults?In response to these unresolved problems and questions in the academic community, Professor Ma Yanlei led a team for four years to conduct fecal metagenomic and metabolomics sequencing analysis on a total of 549 cases of Chinese young intestinal cancer, elderly intestinal cancer and age-matched healthy controls.
